supplementary table 3.
Primary outcomes included efficacy of ciprofol (Satisfaction evaluation
for anesthesiologists, Time to full alertness, Time to successful
anesthesia induction, Time to loss of eyelash reflex, Success rate of
anesthesia, Time required for patients to leave the post-anesthesia care
unit (PACU), Time to respiratory recovery) on anesthesia induction and
maintenance in comparison to propofol.
Secondary outcomes included the safety profile of ciprofol (total
adverse events, tachycardia, rash, prolonged QT interval, pain on
injection (induction), hypoxia, hypotension, hypertension (induction),
CTCAE severity scale (grade 1) (induction), CTCAE severity scale (grade
2) (induction), bradycardia (induction), any treatment-emergent adverse
event, 0.4 mg number of patients who maintained BIS between 40-60 (min)
and 0.4 mg elevated AST (induction and maintenance). This is shown in